Images List Premium Download Classic

Hypertension

Hypertension-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Extracellular vesicles with enhanced potency
October 18, 2018 - N°20180296606

Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.. .
Gas exchange systems and methods for calculating ventilatory threshold and evaluating pulmonary arterial hyertension
October 18, 2018 - N°20180296126

Systems and methods for estimating a ventilatory threshold for a patient and estimating likelihood of pulmonary arterial hypertension are provided. An example method includes determining ratios of minute ventilation to rate of oxygen uptake based on breath-by-breath data for a patient.
Non-invasive blood pressure measurement
October 18, 2018 - N°20180296104

A method of measuring a patient's blood pressure non-invasively considers the shape of the waveform to accurately estimate the patient's invasive systolic and diastolic blood pressure, or alternatively accurately predict the patient's hypertension classification. The method can be implemented in a clinical setting or within a wearable device..
Hypertension Patent Pack
Download 166+ patent application PDFs
Hypertension Patent Applications
Download 166+ Hypertension-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Hypertension-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Aryl acylsulfonamides as blt1 antagonists
October 11, 2018 - N°20180291017

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene b4 receptor 1 (blt1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene b4 receptor 1 (blt1). The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid ...
Composition comprising lactobacillus plantarum 2830 (ecgc 13110402)
October 11, 2018 - N°20180289749

The present invention relates to compositions comprising lactobacillus plantarum 2830 (ecgc 13110402), or mutant strain or strains thereof, for use in the treatment or prevention of hypertension.. .
Treatment of adipocytes
October 11, 2018 - N°20180289707

The present disclosure provides compositions comprising a lyn kinase activator and trpm8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, syndrome x, obesity, prediabetes, type ii diabetes, type i diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator ...
Hypertension Patent Pack
Download 166+ patent application PDFs
Hypertension Patent Applications
Download 166+ Hypertension-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Hypertension-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Flavonolignans for treatment of autoimmune inflammatory diseases
October 11, 2018 - N°20180289666

A method for reducing abnormalities in lipid metabolism and for reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism includes administering an effective amount of a flavonolignan to the subject. The subject may additionally suffer from a liver disease, obesity, hypertension, diabetes mellitus or a metabolic syndrome.
Method and composition for treating ocular hypertension and glaucoma
October 11, 2018 - N°20180289618

The present invention relates to an ophthalmic aqueous composition containing pgf2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of pgf2α analogues in an aqueous composition.. .
Novel azole derivatives as apelin receptor agonist
October 04, 2018 - N°20180282289

The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (i) or a pharmacologically acceptable salt thereof wherein x1 represents —nh═ or —ch═, x2 represents &#...
System and method for optogenetic therapy
October 04, 2018 - N°20180280716

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations.
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
October 04, 2018 - N°20180280445

The current application is directed to a method for treating pulmonary arterial hypertension (pah), comprising: providing isolated endothelial progenitor cells (epcs); treating the epcs with prostacyclin, wherein the treated epcs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated epcs into a subject suffering from pah.. .
Short acting phenylalkylamine calcium channel blockers and uses thereof
October 04, 2018 - N°20180280339

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated ...
Prostamide-containing intraocular implants and methods of use thereof
Allergan, Inc.
September 27, 2018 - N°20180271878

Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the ...
Hypertension Patent Pack
Download 166+ patent application PDFs
Hypertension Patent Applications
Download 166+ Hypertension-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Hypertension-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Renal selective inhibition of cytochrome p450 3a5
September 13, 2018 - N°20180258433

Compositions and methods for treating hypertension in a subject are provided, including administering an antisense oligomer effective to reduce expression of cytochrome p450 3a5 (cyp3a5) enzyme. The antisense oligomer includes phosphorodiamidate morpholino oligonucleotide (pmo), phosphorothioate 2′-o-methyl oligoribonucleotides (pso), locked nucleic acid nucleotide, locked nucleic acid analog nucleotide, or another modified oligonucleotide backbone or nuclease-resistant backbone.
Human endothelin receptor antibody and use thereof
September 13, 2018 - N°20180256714

The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody.
Composition and methods thereof
September 13, 2018 - N°20180256621

The present disclosure relates to composition comprising trigofoenoside, vitexin, iso-vitexin, vitexin-2-o-rhamnoside vicenin-1 and fiber, optionally along with pharmaceutically acceptable excipient(s) and method(s) of preparing said composition. The present disclosure also relates to methods of managing various conditions such as, but not limited to, hypoxia, pulmonary hypertension, pulmonary fibrosis and sinusitis using the said composition..
Agent for enhancing ocular hypotensive effect
September 13, 2018 - N°20180256595

The present invention pertains to a drug available for long-term continuous administration for preventing or treating glaucoma or ocular hypertension, said drug showing no decrease in efficacy during long-term administration and exhibiting a stable ocular hypotensive effect. The present invention pertains to a therapeutic agent for glaucoma or ocular hypertension that is to be continuously administered for a long period ...
System and method for thermal treatment of hypertension, hypotension or aneurysm
September 13, 2018 - N°20180256390

A system for treating a patient with general hypertension by increasing a blood flow in the renal artery. The system comprises a hypertension treatment device adapted to have at least one surface of the device placed on the outside of the renal artery to increase the blood flow in the patient's renal region.
Exo-s-mecamylamine formulation and use in treatment
University Of South Florida
September 06, 2018 - N°20180250244

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg.
Therapeutic agents
Imperial Innovations Limited
August 23, 2018 - N°20180237784

The present invention relates to identification of therapeutic agents for the treatment, diagnosis, and prevention of pulmonary hypertension.. .
Flavonoid compositions and related methods
Instituto De Investigaciones Cientificas Y Servicios De Alta Tecnologia (indicasat Aip)
August 23, 2018 - N°20180235990

Flavonoids that are isolated from plant material of the genus cecropia can be used to perturb g-protein coupled receptors in a mammalian cell. In some instances, one or more flavonoids may interact with one or more of the g-protein coupled receptors to transiently increase the concentration of cytosolic calcium.
Loading